fig6

Figure 6. Establishment of an immune-related risk model in HCC patients. (A and B) LASSO analysis identified 13 variables (MR210HG, AC015908.3, AL031985.3, MYG1-AS1, ZFPM2-AS1, PSMC6, PSMD6, PSMD14, MAPT, MTNR1A, NR6A1, DEFB123, and PTH) associated with HCC patient survival; (C and D) AUROCs evaluating the discrimination power of the risk model in the training and validation phases; (E) Expression levels of the 13 variables in low- and high-risk groups; (F) Immune risk scores of HCC patients in the training and validation phases; (G) Kaplan-Meier analysis showing better prognosis for the low-risk group compared with the high-risk group. Statistical significance assessed using the Wilcoxon rank-sum test. ^*P < 0.05; ^**P < 0.01; ^***P < 0.001. HCC: Hepatocellular carcinoma; LASSO: least absolute shrinkage and selection operator; AUROC: area under the receiver operating characteristic curve.